Caroline M. Geremakis

Suggest Changes
Learn More
BACKGROUND Canagliflozin is the first sodium-glucose co-transporter-2 (SGLT-2) inhibitor-a new class of oral antidiabetic (OAD) medication-approved for type 2 diabetes mellitus (T2DM) treatment in(More)
  • 1